5-Fluorouracil (5-FU) is dosed by body surface area, a practice unable to reduce the interindividual variability in exposure. Endorsed by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), we evaluated clinical evidence and strongly recommend TDM for the management of 5-FU therapy in patients with colorectal or head-and-neck cancer receiving common 5-FU regimens. Our systematic methodology provides a framework to evaluate published evidence in support of TDM recommendations in oncology.

dx.doi.org/10.1002/cpt.1124, hdl.handle.net/1765/110373
Clinical Pharmacology and Therapeutics
Department of Medical Oncology

Beumer, J.H. (Jan H.), Chu, E. (Edward), Allegra, C. (Carmen), Tanigawara, Y. (Yusuke), Milano, G. (Gerard), Diasio, R. (Robert), … Joerger, M. (2018). Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy. Clinical Pharmacology and Therapeutics. doi:10.1002/cpt.1124